Phosphodiesterase (PDE)4 inhibitors: Anti-inflammatory drugs of the future?

被引：182

作者：

Teixeira, MM

Gristwood, RW

Cooper, N

Hellewell, PG

机构：

[1] STEVENAGE LTD, STEVENAGE SG2 8SD, HERTS, ENGLAND

[2] CHIROSCI LTD, CAMBRIDGE CB4 4WE, ENGLAND

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 1997年 / 18卷 / 05期

关键词：

D O I：

10.1016/S0165-6147(97)90613-1

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Phosphodiesterase type 4 (PDE4) plays a major role in modulating the activity of virtually all cells involved in the inflammatory process. Inhibitors of this enzyme family display impressive anti-inflammatory and disease-modifying effects in a variety of experimental models. In this review, Mauro Teixeira, Robert Gristwood, Nicola Cooper and Paul Hellewell examine the capacity of PDE4 inhibitors to exert anti-inflammatory actions in vivo and discuss the potential of this class of drugs to take their place as novel therapeutic agents for a variety of inflammatory diseases.

引用

页码：164 / 170

页数：7

共 101 条

[1]

ALVAREZ R, 1995, MOL PHARMACOL, V48, P616

[2]

BADGER AM, 1994, CIRC SHOCK, V44, P188

[3] ACUTE VERSUS CHRONIC ADMINISTRATION OF PHOSPHODIESTERASE INHIBITORS ON ALLERGEN-INDUCED PULMONARY CELL INFLUX IN SENSITIZED GUINEA-PIGS [J].